Advancing Outcomes with Digital Medicine

Biofourmis is accelerating drug development, clinical research, and the use of Software as a Medical Device (SaMD) with breakthrough innovation

The Biofourmis Digital Medicine Approach

Utilizing one of the only FDA-cleared algorithms, Biofourmis accelerates product innovation and clinical research with its holistic, end-to-end solution.

Digital Therapeutics

Biofourmis is pioneering a new category of medicine by developing clinically-validated, software-based therapeutics to treat and manage patients with unmet clinical needs. These digital therapeutics work independently or in conjunction with pharmacotherapies – augmenting drug efficacy, reducing costs and driving better patient outcomes.

Pharmaceutical companies prescribe digital therapeutics as a companion therapy with high-value drugs to improve efficacy and to better manage and treat patients with complex chronic conditions.

Utilize patient-centric biomarkers as surrogate endpoints to achieve primary and secondary clinical trial endpoints
Enable early disease detection and improved drug dosing titration based on clinically-validated, software-based medicine
Improve patient engagement, track side-effects/adverse events and personalize treatment using combination therapy with Software as a Medical Device (SaMD)
Improve outcomes through predictive interventions based on machine learning (ML) of physiological measures and vitals

Decentralized Clinical Trials (DCTs)

Biofourmis is reducing clinical trial timelines by supporting patient data capture in decentralized and virtual clinical studies. Our DCT solution offers many features such as telehealth, active ePRO and passive sensor data collection, a comprehensive patient kit and provisioning service, AI algorithm development, predictive data sciences and digital clinical research services.

Speed up clinical trials with novel, patient-centric biomarkers as surrogate endpoints
Improve recruitment and remote patient monitoring with active and passive data collection
Enhance patient-centric solutions with configurable journeys, alerts, vitals, and validated questionnaires and outcomes
Utilize user-friendly interfaces to reduce site burden and increase satisfaction for healthcare professionals
Objective measurement of safety signals from an FDA-cleared platform

Commercialization and Market Access

Utilized by companies to help commercial, market access, and medication adherence, Biofourmis is supporting real-world usage to improve outcomes and increase effectiveness of various drugs and devices. The Biovitals Index, with its machine learning and AI analytics, monitors for safety events and provides notifications to highlight significant patient changes.

Partner Use Cases

Digital Medicine with Chugai Pharmaceutical CO., LTD

Chugai is objectively assessing pain associated with endometriosis to better understand its pathology and treatment.

Decentralized Clinical Trials with the University of Hong Kong

The University of Hong Kong is utilizing the Biovitals Index to remotely monitor and identify COVID-19-related physiological biomarkers that indicate deterioration in patients.

Commercialization with Novartis

Novartis is partnering with Biofourmis to monitor heart-failure patients who are taking Novartis’ Entresto drug in an effort to reduce hospital readmissions and emergency-room visits.

Digital Medicine Pipeline

Our digital medicine portfolio consists of products that cover multiple medicine areas, including heart failure, acute coronary syndrome, COPD, oncology, and chronic pain.

Download the whitepaper today: Accelerating Biopharmaceutical Innovation With Digital Therapeutics To Improve Patients’ Quality Of Life

The evolution of healthcare technology and personalized AI-based technologies are revolutionizing the way we approach medicine. Learn more about how you can accelerate innovation with digital medicine to improve patient outcomes. Download this reference guide to initiate your virtual care program to realize improved outcomes and efficiencies

Trusted by Leading Health Systems, Providers, Pharmaceutical Companies, and More

What Our Customers Are Saying

“Through the partnership with Biofourmis, a leading company in research, development and commercialization of digital medicine, Chugai will set out to objectively assess pain associated with endometriosis and better understand its pathology.”

"The Everion^® biosensor has become part of my daily habit. I wear it and forget about it and I know a care team is always there to make sure I am safe."

"The goal of this program is to leverage Biovitals^® to remotely monitor patients and identify COVID-19 related physiological biomarkers that indicate deterioration in patients."